Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Anna Asklid, Sandra Eketorp Sylvan, Agnes Mattsson, Maria Winqvist, Hemming Johansson, Anders Österborg & Lotta Hansson. (2020) A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy. Leukemia & Lymphoma 61:9, pages 2136-2144.
Read now
Read now
Kensuke Kayamori, Katsuhiro Shono, Masahiro Onoda & Akira Yokota. (2019) Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. Hematology 24:1, pages 52-59.
Read now
Read now
Annalisa Chiappella, Alessia Castellino, Maura Nicolosi, Elisa Santambrogio & Umberto Vitolo. (2017) Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. Expert Review of Hematology 10:4, pages 289-297.
Read now
Read now
Yotaro Ochi, Nobuhiro Hiramoto, Yuichiro Ono, Satoshi Yoshioka, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Yukihiro Imai & Takayuki Ishikawa. (2016) Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis. Leukemia & Lymphoma 57:8, pages 1945-1948.
Read now
Read now
Articles from other publishers (16)
H. F. Fisher, R. J. Boys, C. S. Gillespie, C. J. Proctor & A. Golightly. (2021) Parameter inference for a stochastic kinetic model of expanded polyglutamine proteins. Biometrics 78:3, pages 1195-1208.
Crossref
Crossref
Marguerite Briand, Stephane Gerard, Martin Gauthier, Marie Garric, Zara Steinmeyer & Laurent Balardy. (2021) Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B‐cell lymphoma on survival: A systematic review. European Journal of Haematology 108:1, pages 3-17.
Crossref
Crossref
Alda Tavares & Ilídia Moreira. (2021) Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment – A systematic review. Critical Reviews in Oncology/Hematology 160, pages 103294.
Crossref
Crossref
Alden A. Moccia & Catherine Thieblemont. (2018) Curing diffuse large B-cell lymphomas in elderly patients. European Journal of Internal Medicine 58, pages 14-21.
Crossref
Crossref
Wen-Hao Zhang, Gao-Yang Li, Yu-Jie Ma, Zhi-Chao Li, Yang Zhu, Jun Chang, Si-Guo Hao & Rong Tao. (2018) Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma. Annals of Hematology 97:10, pages 1809-1816.
Crossref
Crossref
Chieh-Lung Cheng, Jia-Hau Liu, Sheng-Chieh Chou, Ming Yao, Jih-Luh Tang & Hwei-Fang Tien. (2018) Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. European Journal of Haematology 101:1, pages 28-37.
Crossref
Crossref
Michael Tallarico, Jared C. Foster, Drew Seisler, Jacqueline M. Lafky, Arti Hurria, Aminah Jatoi, Harvey J. Cohen, Hyman B. Muss, Nancy Bartlett, Bruce D. Cheson, Sin-Ho Jung, John P. Leonard, John C. Byrd & Chadi Nabhan. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). Journal of Geriatric Oncology 9:4, pages 321-328.
Crossref
Crossref
Yuzuru Hosoda, Norihiko Hino & Toru Motokura. (2018) Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area. Yonago Acta Medica 61:1, pages 058-065.
Crossref
Crossref
Yotaro Ochi, Yasuhiro Kazuma, Nobuhiro Hiramoto, Yuichiro Ono, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita, Yukihiro Imai, Hisako Hashimoto & Takayuki Ishikawa. (2016) Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Annals of Hematology 96:1, pages 1-8.
Crossref
Crossref
Annalisa Chiappella, Alessia Castellino & Umberto Vitolo. (2016) State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1147-1162.
Crossref
Crossref
Sridhar Chaganti, Tim Illidge, Sally Barrington, Pam Mckay, Kim Linton, Kate Cwynarski, Andrew McMillan, Andy Davies, Simon Stern & Karl Peggs. (2016) Guidelines for the management of diffuse large B-cell lymphoma. British Journal of Haematology 174:1, pages 43-56.
Crossref
Crossref
Futoshi Iioka, Kiyotaka Izumi, Yoshimasa Kamoda, Takashi Akasaka & Hitoshi Ohno. (2015) Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. International Journal of Clinical Oncology 21:3, pages 498-505.
Crossref
Crossref
Sung-Hoon Jung, Je-Jung Lee, Won Seog Kim, Won-Sik Lee, Young Rok Do, Sung Yong Oh, Min Kyoung Kim, Yeung-Chul Mun, Ho-Jin Shin, Jae-Yong Kwak, Hye Jin Kang, Jong Ho Won, Jung Hye Kwon, Eunkyung Park, Cheolwon Suh & Deok-Hwan Yang. (2015) Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). European Journal of Haematology 94:6, pages 504-510.
Crossref
Crossref
Susana Salva, Gabriela Marranzino, Julio Villena, Graciela Agüero & Susana Alvarez. (2014) Probiotic Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice. International Immunopharmacology 22:1, pages 209-221.
Crossref
Crossref
Stephan Kreher, Felicitas Lammer, Dieter Augustin, Antonio Pezzutto & Claudia D. Baldus. (2014)
R‐split‐
CHOP
chemotherapy for elderly patients with diffuse large B‐cell lymphoma
. European Journal of Haematology 93:1, pages 70-76.
Crossref
Crossref
Stephen D. Smith, Andy Chen, Stephen Spurgeon, Craig Okada, Guang Fan, Jennifer Dunlap, Rita Braziel & Richard Maziarz. (2013) Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors. Therapeutic Advances in Hematology 4:6, pages 349-353.
Crossref
Crossref